ArticleCancer science2008
Plasma midkine level is a prognostic factor for human neuroblastoma.
Article in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target.Cancer letters · 2026Review
- Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting.International journal of molecular sciences · 2023Review
- The role of midkine in health and disease.Frontiers in immunology · 2023Review
- Screening of novel Midkine binding protein by BioID2-based proximity labeling.Nagoya journal of medical science · 2021Article
- Evaluation of serum midkine and carcinoembryonic antigen as diagnostic biomarkers for rectal cancer and synchronous metastasis.Translational cancer research · 2020Article
- Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.Oncogene · 2020Review
- Serum Midkine is a clinical significant biomarker for colorectal cancer and associated with poor survival.Cancer medicine · 2020Observational
- Influence of Menopause on Inflammatory Cytokines during Murine and Human Bone Fracture Healing.International journal of molecular sciences · 2018Article
- Prognostic value of Midkine expression in patients with solid tumors: a systematic review and meta-analysis.Oncotarget · 2018Article
- Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.The American journal of pathology · 2016Article
- Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma.Cancer medicine · 2016Article
- Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.British journal of pharmacology · 2014Review
- Midkine promotes perineural invasion in human pancreatic cancer.World journal of gastroenterology · 2014Article
- Involvement of midkine in neuroblastoma tumourigenesis.British journal of pharmacology · 2014Review
- The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.The Journal of biological chemistry · 2013Article
- Midkine Mediates Intercellular Crosstalk between Drug-Resistant and Drug-Sensitive Neuroblastoma Cells In Vitro and In Vivo.ISRN oncology · 2013Article
- Midkine: a promising molecule for drug development to treat diseases of the central nervous system.Current pharmaceutical design · 2011Review
- A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.Molecular cancer · 2010Article
- Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer.Journal of experimental & clinical cancer research : CR · 2010Article
- Midkine: a novel prognostic biomarker for cancer.Cancers · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is the third-most-common solid tumor of childhood. To date, no reliable blood marker for neuroblastoma has been established. The growth factor midkine is highly expressed in human carcinomas and its knockdown leads to tumor growth suppression in animal models. The present study evaluated the plasma midkine level in human neuroblastoma patients. Plasma samples were obtained from patients found through mass screening, as well as from sporadic neuroblastoma patients. The total number of cases examined was 756. Among them, prognostic information was available for 175 sporadic cases and 287 mass-screening cases. Midkine levels were significantly higher in neuroblastoma patients, including both mass-screening cases and sporadic cases, than in non-tumor controls (P < 0.0001). The midkine level was significantly correlated with the statuses of MYCN amplification, TRKA expression, ploidy, stage and age (P < 0.0001, < 0.0001, = 0.004, < 0.0001 and < 0.0001, respectively), which are known prognostic factors for neuroblastoma. There was a striking correlation between high plasma midkine level and poor prognosis (P < 0.0001). Within sporadic cases, the midkine level was also strikingly higher than in non-tumor controls (P < 0.0001), and correlated with the statuses of MYCN amplification and stage (P = 0.0005 and = 0.003, respectively). There was a significant correlation between high plasma midkine level and poor prognosis (P = 0.04). Taken together, the present data indicate that plasma midkine level is a prognostic factor for human neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.